Artículos de revistas
Peptic Ulcer [Úlcera Péptica]
Registro en:
Revista Brasileira De Medicina. , v. 60, n. SPEC. ISS., p. 25 - 32, 2003.
347264
2-s2.0-0742305954
Autor
Monici L.T.
Zeitune J.M.R.
Lorena S.L.S.
Mesquita M.A.A.
De Magalhaes A.F.N.
Institución
Resumen
Peptic ulcer is a common disease. The Helicobacter pylori infection and the use of anti-inflammatory drugs are the main risk factors. There is no characteristic clinical finding and some patients have no symptom. Epigastric pain is a common finding and is associated with food. The diagnosis is done by upper gastrointestinal endoscopy and endoscopic biopsies can identificate H.pylori. Eradication of the organism is the therapy of choice in infected patients. Drugs that inhibit acid gastric secretion can promote ulcer healing in almost all patients. The protom pump inhibitors are the most effective. They can be used in prevention of ulcer in high risk patients that use anti-inflammatory, as in elderly, patients with severe comorbid conditions and patients taking corticosteroids or anticoagulants. 60 SPEC. ISS. 25 32 Kurata, J.H., Epidemiology of peptic ulcer disease (1984) Clin Gastroenterol, 13, p. 289 Munnangi, S., Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States (1997) Arch Intern Med, 157, pp. 1489-1494 Higham, J., Kang, J.Y., Majeed, A., Recent trends in admissions and mortality due to peptic ulcer in England: Increasing frequency of haemorrhage among older subjects (2002) Gut, 50, pp. 460-464 Marshall, B.J., Warren, J.R., Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcerations (1984) Lancet, 1, pp. 1311-1315 Cohen, H., Peptic ulcer and Helicobacter pylori (2000) Gastroenterol Clin North Am, 29, p. 775 El-Omar, E.M., Penman, I.D., Ardill, J.E., Chittajallu, R.S., Howie, C., McColl, K.E., Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease (1995) Gastroenterology, 109, pp. 681-691 Beales, I., Calam, J., Post, L., Effect of transforming growth factor alpha and interleukin 8 on somatostatin release from canine fundic D cells (1997) Gastroenterology, 112, pp. 136-143 Hogan, D.L., Rapier, R.C., Dreilinger, A., Duodenal bicarbonate secretion: Eradication of Helicobacter pylori and duodenal structure and function in humans (1996) Gastroenterology, 110, pp. 705-716 Segal, E.D., Cha, J., Lo, J., Falkow, S., Tompkins, L.S., Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori (1999) Proc Natl Acad Sci USA, 96, pp. 14559-14564 Uemura, N., Okamoto, S., Yamamoto, S., Helicobacter infection and the development of gastric cancer (2001) N Engl J Med, 345, pp. 784-789 Wolfe, M.M., Lichtenstein, D.R., Singh, G., Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs (1999) N Engl J Med, 340, p. 1888 Wallace, J.L., Keenan, C.M., Granger, D.N., Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process (1990) Am J Physiol, 259, pp. 462-467 Silverstein, F.E., Faich, G., Goldstein, J.L., Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflamamatory drugs for osteoarthritis and rheumatoid arthritis (2000) JAMA, 284, pp. 1247-1255 Wallace, J.L., McKnight, W., Reuter, B.K., Vergnolle, N., NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2 (2000) Gastroenterology, 119, pp. 706-714 Huang, J.Q., Sridhar, S., Hunt, R.H., Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis (2002) Lancet, 359, pp. 14-22 Zeitune, J.M.R., Monici, L.T., Nishimura, N.F., Diagnóstico da infecção pelo Helicobacter pylori (2000) Gastroenterologia III/Farid Nader, , Pelotas: Editora Universitária Borody, T.J., Cole, P., Noonan, S., Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication (1989) Med J Aust, 151, pp. 431-435 Porro, G.B., Parente, F., Antacids for duodenal ulcer: Current role (1990) Scand J Gastroenterol, 25, p. 48 Deakin, M., Williams, J.G., Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers (1992) Drugs, 44, p. 709 Lee, F.I., Collin-Jones, D.G., Golding, P.L., Double-blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: A multicentre trial (1991) Gut, 26, p. 137 Malfertheiner, P., Megraud, F., O'Morain, C., Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000 Consensus Report (2002) Aliment Pharmacol Ther, 16, pp. 167-180 Vaira, D., Vakil, N., Menegatti, M., The stool antigen test for detection of Helicobacter pylori after eradication therapy (2002) Ann Intern Med, 136, pp. 280-287 Yeomans, N.D., Tulassay, Z., Juhasz, L., Omeprazole compared with ranitidine for ulcers associated with nonsteroidal antiinflamatory drugs (1998) N Engl J Med, 338, pp. 719-726 Rich, M., Scheiman, J., Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: Mechanisms and prevention (2000) Sem Arthritis Rheum, 30, p. 167 Norton, J., Surgery to cure Zollinger-Ellison syndrome (1999) N Engl J Med, 341, p. 635